Abstract
Rituximab, a chimeric anti-CD20 monoclonal antibody, is used to treat rheumatologic and hematologic diseases. Serum sickness, a Type III delayed hypersensitivity reaction, has been reported with rituximab treatment. Traditionally, drug desensitization has been used to treat Type I IgE-mediated hypersensitivity reactions. We report the first case of successful drug desensitization to rituximab in a patient with medication-induced serum sickness. In our case, a 37-year-old woman with Sjogren’s syndrome and papillary thyroid carcinoma developed serum sickness 72 hours following rituximab infusion for gastric mucosal associated lymphoma tissue (MALT). Her MALT progressed after stopping rituximab. She underwent a rapid 12-step intravenous rituximab desensitization without recurrence of serum sickness. Following the completion of 4 rituximab desensitizations, she had gastric MALT remission. She received 25 maintenance rituximab doses using this desensitization protocol quarterly without complications. This is the first report documenting rituximab desensitization for the treatment of delayed drug reactions like serum sickness.
Keywords: Desensitization, hypersensitivity, mucosa associated lymphoid tissue, rituximab, serum sickness.
Current Drug Safety
Title:Desensitization Protocol for Rituximab-Induced Serum Sickness
Volume: 9 Issue: 3
Author(s): Merritt L. Fajt and Andrej A. Petrov
Affiliation:
Keywords: Desensitization, hypersensitivity, mucosa associated lymphoid tissue, rituximab, serum sickness.
Abstract: Rituximab, a chimeric anti-CD20 monoclonal antibody, is used to treat rheumatologic and hematologic diseases. Serum sickness, a Type III delayed hypersensitivity reaction, has been reported with rituximab treatment. Traditionally, drug desensitization has been used to treat Type I IgE-mediated hypersensitivity reactions. We report the first case of successful drug desensitization to rituximab in a patient with medication-induced serum sickness. In our case, a 37-year-old woman with Sjogren’s syndrome and papillary thyroid carcinoma developed serum sickness 72 hours following rituximab infusion for gastric mucosal associated lymphoma tissue (MALT). Her MALT progressed after stopping rituximab. She underwent a rapid 12-step intravenous rituximab desensitization without recurrence of serum sickness. Following the completion of 4 rituximab desensitizations, she had gastric MALT remission. She received 25 maintenance rituximab doses using this desensitization protocol quarterly without complications. This is the first report documenting rituximab desensitization for the treatment of delayed drug reactions like serum sickness.
Export Options
About this article
Cite this article as:
Fajt L. Merritt and Petrov A. Andrej, Desensitization Protocol for Rituximab-Induced Serum Sickness, Current Drug Safety 2014; 9 (3) . https://dx.doi.org/10.2174/1574886309666140509154056
DOI https://dx.doi.org/10.2174/1574886309666140509154056 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Omalizumab: Not Only For Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Human Plasma Kallikrein-Kinin System: Physiological and Biochemical Parameters
Cardiovascular & Hematological Agents in Medicinal Chemistry Cytokine and Nitric Oxide Production Following Severe Envenomation
Current Drug Targets - Inflammation & Allergy RAAS Inhibition and Cardiorenal Syndrome
Current Hypertension Reviews Editorial [Hot Topic:Mimetic Peptides in Allergy and Inflammation Treatment (Guest Editor: Demitrios H. Vynios)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel Possible Pharmaceutical Research Tools: Stem Cells, Gene Delivery and their Combination
Current Pharmaceutical Design Biologic Agents in the Treatment of Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Current Indications for Infective Endocarditis Antibiotic Prophylaxis
Infectious Disorders - Drug Targets The ONTARGET Trial Programme: Facts and Lessons
Current Hypertension Reviews Aspirin Intolerance: Experimental Models for Bed-to-Bench
Current Drug Targets The Indian Pediatric HIV Epidemic: A Systematic Review
Current HIV Research Isolated Perioperative Hypertension: Clinical Implications & Contemporary Treatment Strategies
Current Hypertension Reviews Multiscale Modelling of Relationships between Protein Classes and Drug Behavior Across all Diseases Using the CANDO Platform
Mini-Reviews in Medicinal Chemistry Monoclonal Antibodies in Allergy; Updated Applications and Promising Trials
Recent Patents on Inflammation & Allergy Drug Discovery Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
Current Pharmaceutical Design Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Kawasaki Disease and Its Treatment – An Update
Current Rheumatology Reviews Skin Tests in the Diagnosis of Drug Hypersensitivity Reactions
Current Pharmaceutical Design Hypertension in Children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Current Hypertension Reviews